Enoxaparin's potential mechanisms against SARS-CoV-2.
作者信息
Afsharirad Bentelhoda, Entezari-Maleki Taher
机构信息
Department of Clinical Pharmacy, Faculty of Pharmacy.
Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
出版信息
Int J Surg. 2023 Jan 1;109(1):48-49. doi: 10.1097/JS9.0000000000000081.
Abstract
摘要
相似文献
1
Enoxaparin's potential mechanisms against SARS-CoV-2.依诺肝素抗新型冠状病毒的潜在机制。
Int J Surg. 2023 Jan 1;109(1):48-49. doi: 10.1097/JS9.0000000000000081.
2
The impact of different prophylactic anticoagulation doses on the outcomes of patients with COVID-19.不同预防性抗凝剂量对新型冠状病毒肺炎患者预后的影响。
Thromb Res. 2021 Jun;202:14-16. doi: 10.1016/j.thromres.2021.02.031. Epub 2021 Mar 6.
3
Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin.肝素抑制 SARS-CoV-2 的细胞侵袭：刺突 S1 受体结合域与肝素相互作用的结构依赖性。
Thromb Haemost. 2020 Dec;120(12):1700-1715. doi: 10.1055/s-0040-1721319. Epub 2020 Dec 23.
4
[Pharmacological and clinical profiles of the anticoagulant enoxaparin sodium (Clexane 2000 IU S.C. Inj. Kit)].[抗凝剂依诺肝素钠（克赛2000IU皮下注射试剂盒）的药理学与临床概况]
Nihon Yakurigaku Zasshi. 2009 Feb;133(2):91-8. doi: 10.1254/fpj.133.91.
5
High-Dose Prophylactic Anticoagulation in Severe COVID-19 Pneumonia.重症新型冠状病毒肺炎的大剂量预防性抗凝治疗
Chest. 2021 Jul;160(1):e94-e95. doi: 10.1016/j.chest.2021.02.036.
6
Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin.低分子量肝素治疗剂量的临床经验。
Infez Med. 2020 Jun 1;28(suppl 1):118-121.
7
[Comment on article "Enoxaparin dose associated with decreased risk of death in COVID-19"].[关于文章《与新冠肺炎死亡风险降低相关的依诺肝素剂量》的评论]
Rev Med Inst Mex Seguro Soc. 2022 May 2;60(3):247-248.
8
First case report of a successfully managed severe COVID-19 infection in Malawi.马拉维成功治愈严重新冠病毒感染的首例病例报告。
Malawi Med J. 2020 Dec;32(4):226-228. doi: 10.4314/mmj.v32i4.8.
9
Enoxaparin 40 mg per Day Is Inadequate for Venous Thromboembolism Prophylaxis After Thoracic Surgical Procedure.每天 40 毫克依诺肝素不足以预防胸外科手术后的静脉血栓栓塞症。
Ann Thorac Surg. 2018 Aug;106(2):404-411. doi: 10.1016/j.athoracsur.2018.02.085. Epub 2018 Apr 5.
10
A case of Evans syndrome secondary to COVID-19.一例继发于新型冠状病毒肺炎的伊文氏综合征病例。
Blood Transfus. 2021 Jan;19(1):85-88. doi: 10.2450/2020.0221-20. Epub 2020 Dec 1.
引用本文的文献
1
Disrupting SARS-CoV-2 Spike-ACE2 Interactions via Glycosaminoglycans in a Pseudoviral Study of Heparan Sulfate and Enoxaparin.在一项关于硫酸乙酰肝素和依诺肝素的假病毒研究中，通过糖胺聚糖破坏严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白与血管紧张素转换酶2（ACE2）的相互作用
Biomolecules. 2025 Jun 26;15(7):931. doi: 10.3390/biom15070931.
Zotero 插件